Danaher Corporation $DHR Shares Bought by Price T Rowe Associates Inc. MD

Key Points

• Price T Rowe Associates Inc. MD increased its holdings in Danaher Corporation by 3.2%, purchasing an additional 612,154 shares, bringing its total ownership to approximately 2.74% of the company, valued at $4.02 billion.
• Danaher Corporation reported robust earnings, with a quarterly EPS of $1.80, exceeding the consensus estimate of $1.64, and revenues of $5.94 billion, slightly above expectations.
• Analysts have shown a positive outlook for Danaher, with the majority rating it as a "Moderate Buy" and a target price average of $247.61, despite some recent reductions in price targets from various firms.

Price T Rowe Associates Inc. MD raised its stake in Danaher Corporation (NYSE:DHR - Free Report) by 3.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 19,592,211 shares of the conglomerate's stock after acquiring an additional 612,154 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.74% of Danaher worth $4,016,404,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Nuveen LLC acquired a new position in Danaher during the first quarter valued at approximately $833,941,000. GAMMA Investing LLC raised its holdings in shares of Danaher by 24,958.2% during the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock valued at $383,524,000 after purchasing an additional 1,863,381 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Danaher by 4,248.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock valued at $376,347,000 after purchasing an additional 1,601,800 shares during the period. Invesco Ltd. raised its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in Danaher by 460.6% in the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after purchasing an additional 1,107,998 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on DHR shares. Barclays reaffirmed an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Evercore ISI lowered their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company decreased their price objective on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Finally, UBS Group cut their target price on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Danaher has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Price Performance

NYSE DHR traded down $3.9090 on Monday, hitting $207.8910. The company had a trading volume of 1,972,823 shares, compared to its average volume of 4,205,166. The company has a market capitalization of $148.86 billion, a PE ratio of 44.23, a PEG ratio of 2.96 and a beta of 0.73. The company's fifty day moving average price is $200.67 and its 200-day moving average price is $199.37. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the prior year, the firm earned $1.72 EPS. Danaher's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.